Role Of Pancreofly in Diabetes Type 2

A RANDOMISED COMPARATIVE MULTICENTRIC CLINICAL TRIAL TO EVALUATE SAFETY & EFFICACY OF A POLYHERBAL FORMULATION (PANCREOFLY) IN CONTROLLING BLOOD SUGAR LEVEL IN Type-2 DIABETES MELLITUS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/014341

Enrollment

Registered

2018-05-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 diabetes

Interventions

Intervention1: Pancreofly Capsule: Polyherbal compound Control Intervention1: Glycomet: Metformin 500 mg BD for 90 days

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 Diabetes mellitus

Exclusion criteria

Exclusion criteria: complications of Diabetes

Design outcomes

Primary

Measure	Time frame
1.Marked improvement : 0% to 25 % 2.Moderate improvement : 25 % to 50 % 3.Mild improvement : 50% to 75 % 4.No improvement : 75% to 100% Timepoint: Assessment on every 15th day of trial	—

Secondary

Measure	Time frame
1.Marked improvement : 0% to 25 % 2.Moderate improvement : 25 % to 50 % 3.Mild improvement : 50% to 75 % 4.No improvement : 75% to 100% Timepoint: Assessment on every 15th day of trial	—

Countries

India

Contacts

Public ContactDr Alok Kumar Srivastava

Uttarakhand Ayurved University

virgo.alok@gmail.com9045087121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026